TrialEndocrine-related cancer2016

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

Martyn E Caplin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.